In-Silico Docking Studies of Angiotensin Converting Enzyme Using Natural Inhibitor

Abstract

Lowering blood pressure (BP) using antihypertensive medicines lowers the risk of target organ failure as well as the occurrence of cardiovascular disease. The most common modifiable risk factor for death and disability is hypertension, which is associated with strokes, increased coronary and systemic atherosclerosis, heart problems, and chronic kidney diseases (CKD). The majority of deaths and disabilities globally now result from cardiovascular diseases (CVDs), mainly in low- and middle-income nations. Numerous genetic, behavioral, and environmental risk factors all contribute to hypertension, a significant component in the advancement of CVD. Given the significance of protein-ligand interactions in structure-based therapy development, we molecularly docked nifedipine to the cardiovascular target protein to determine the drug’s binding affinity. The Angiotensin Converting Enzyme (Target hypertension Protein) three-dimensional (3D) structure was docked using the Autodock tool, which was retrieved from the Protein Data Bank (PDB). Our analysis indicates that nifedipine is an effective choice for treating hypertension and reducing the symptoms of angina (chest pain).

Imprint

Vijay Laxmi, Pinki Chakraborty, Kirtimaya Mishra. In-Silico Docking Studies of Angiotensin Converting Enzyme Using Natural Inhibitor. Cardiometry; Issue 24; November 2022; p.1046-1052; DOI: 10.18137/cardiometry.2022.24.10461052; Available from: https://www.cardiometry.net/issues/no24-november-2022/in-silico-docking-studies